THE RESULTS OF OUR FEBRILE NEUTROPENIA MANAGEMENT REPORTS FOR THREE YEARS
Abstract number: P-M-408
Sayilan Sen1 H.H.S., Salcioglu1 Z., Akici1 F., Aydogan1 G., Ulucakli1 O., Yanilmaz1 O., Aktay Ayaz1 N., Aldemir1 H.
1clinics of pediatric hematology-onkology, Ministry of health Istanbul Bakirkoy women and children diseases education hospital, istanbul, Turkey
How-to-cite Sayilan Sen HHS, Salcioglu Z, Akici F, Aydogan G, Ulucakli O, Yanilmaz O, Aktay Ayaz N, Aldemir H. THE RESULTS OF OUR FEBRILE NEUTROPENIA MANAGEMENT REPORTS FOR THREE YEARS. J Thromb Haemost 2007; 5 Supplement 2: P-M-408
Introduction: Hematological and oncological diseases, different immune deficiency casesand chemoterapy regimens can cause neutropenia. Whatever the cause is neutropenia leads to the development of infections.
Methods: We have evalutaed 197 cases having 527 febrile neutropenia attacks during January 2003 and January 2006 retrospectively.
Results: Of the patients 243 (46.1%) were females and 284 (53.9%) were males. Origin of fever could not be found in 35% of neutropenic patients (186 attacks). In 10.6% of the patients (56 attacks) lung involvement, in 9.7% (51 attacks) gastrointestinal involvement, in 6.8% (36 attacks) blood, in 6.5% (34 attacks) severe mucositis and in 6.5% (34 attacks) urinary involvement were detected.
In 83 attacks (15.7%) there were positive hemocultures. Culture results were; Staph. Epidermidis in 40.9% (34), Gr (-) rods in 25.3% (21), Enterobacter in 14.4% (12), Klebsiella in 0.5% (4). In 303 attacks (57.5%) monotherapy with carbapenem, in 33 attacks (6.3%) combination therapy with carbapenem and aminoglycosides were given. In 191 attacks (36.2%) different antibiotic regimens were used.
Attacks according to the diseases were; 271 (51.4%) ALL, 66 (12.5%) neuroblastoma, 55 (10.4%) ANLL, 42 (8%) NHL. The duration of neutropenia was between 3 and 105 days (14.12).Growth factor was used in 330 (62%) of the attacks. Modification of the antibiotherapy was done in 254 attacks (48%). Antifungal therapy was added in 168 attacks (31.9%). Of these patients 27 (5.1%) were lost with etiologies added to febrile neutropenia.
Conclusions: We pointed out the efficiency of monotherapy and the intensification of efficiency with different modifications of monotherapy.
To cite this abstract use the following format:
Journal of Thrombosis and Haemostasis 2007; Volume 5, Supplement 2: abstract number
||XXIst ISTH Congress
| Back to top